3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Breast
1
Conditions
Pain, Postoperative
5
Breast Neoplasms
3
Thyroid Neoplasms
2
Chronic Pain
2
Brain Neoplasms
2
Agnosia
2
Urinary Bladder Neoplasms
1
Thrombosis
1
Sleep Initiation and Maintenance Disorders
1
Sigmoid Neoplasms
1
Sarcoma
1
Rectal Neoplasms
1
Pain
1
Opioid Consumption, Postoperative
1
Neuroinflammatory Diseases
1
Meningioma
1
Lung Injury
1
Inflammation
1
Hypoxia
1
Hyperthyroidism
1
Goiter
1
Elderly
1
Delirium
1
Colorectal Neoplasms
1
Breast Cancer Female
1
Abdominal Cancer Surgeries
1
Interventions
Letrozole
2
Bupivacaine
2
pyrotinib
1
exemestane
1
abemaciclib
1
Tumor Burden
1
Thioctic Acid
1
Tamoxifen
1
Surveys and Questionnaires
1
Surgical Procedures, Operative
1
Sodium Chloride
1
Ropivacaine
1
Radiotherapy
1
Radiofrequency Ablation
1
Mastectomy, Segmental
1
Mastectomy
1
Mammaplasty
1
Drug Therapy
1
Dexmedetomidine
1
Control Groups
1
Anastrozole
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Breast Cancer Female
×
Dexmedetomidine
×
1 year
×
Clear all
NCT03063073
2026-02-12
pec's
South Egypt Cancer Institute
Phase 3
Completed
60 enrolled